Anthrax immune globulin - Emergent BioSolutions (Cangene)

Drug Profile

Anthrax immune globulin - Emergent BioSolutions (Cangene)

Alternative Names: AIGIV; Anthrasil; Anthrax immune globulin - Cangene; Anthrax immune globulin intravenous; NP-015

Latest Information Update: 04 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cangene Corporation
  • Developer Emergent BioSolutions
  • Class Antibacterials; Immunoglobulins; Polyclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Anthrax
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anthrax

Most Recent Events

  • 31 Aug 2015 Launched for Anthrax (Combination therapy) in USA (IV)
  • 24 Mar 2015 Registered for Anthrax (Combination therapy) in USA (IV)
  • 07 Aug 2014 Preregistration for Anthrax in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top